Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
Novo submits sickle cell drug for regulatory approval
00

Novo submits sickle cell drug for regulatory approval

Nov 13, 2026

Novo Nordisk submitted approval applications to the FDA and EMA on November 13, 2026, for etavopivat, a once-daily oral therapy for sickle cell disease in patients aged 12 and older. Acquired in a $1 billion buyout of Forma Therapeutics in 2022, etavopivat reduced annual painful vaso-occlusive crises by 27% and delayed the first crisis by four months in Phase 3 trials. Regulators are expected to act in 2027 on the drug, which Novo Nordisk views as a potential future blockbuster.

Regulatory submissions and designations

  • ▪On November 13, 2026, Novo Nordisk submitted a New Drug Application to the U.S. FDA and a Marketing Authorization Application to the EMA for etavopivat to treat sickle cell disease in patients aged 12 and older
  • ▪The U.S. FDA previously granted etavopivat Fast Track, Rare Pediatric Disease, and Orphan Drug designations for the treatment of sickle cell disease
  • ▪The European Commission granted etavopivat Orphan Drug designation based on a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products

Novo Nordisk statements and goals

  • ▪Martin Holst Lange, chief scientific officer at Novo Nordisk, stated that etavopivat could provide a new disease-modifying treatment option for people living with sickle cell disease if approved
  • ▪Martin Holst Lange stated that Novo Nordisk intends to work alongside the sickle cell community to advance health equity and address longstanding health disparities
  • ▪Novo Nordisk announced in an earnings presentation that it aims to position etavopivat as a new standard of care for sickle cell disease and views the treatment as a potential future blockbuster

Clinical trials of etavopivat

  • ▪The phase 3b HIBISCUS 2 trial is evaluating once-daily etavopivat against placebo in an expected 510 patients aged 12 and older with sickle cell disease
  • ▪Novo Nordisk is also evaluating etavopivat in mid-stage clinical testing for the treatment of thalassemia, another blood condition

2 sources

BioSpace
Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval - BioSpace
View source article
BioPharma Dive
Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
View source article

Story comments

Loading comments…

Related entities

United StatesSickle Cell diseaseEuropean Commission

Related Projects

European Medicines Agency

Topics

Clinical trialsFast track designationHematologyDrug Policy, Pricing & ApprovalFDA drug approvalOrphan drug designationNovo NordiskPharmaceutical IndustryRare diseases